Channel Therapeutics Corporation (AMEX:CHRO) has a beta value of 3.78 and has seen 0.59 million shares traded in the recent trading session. The company, currently valued at $6.22M, closed the recent trade at $1.02 per share which meant it lost -$0.05 on the day or -4.67% during that session. The CHRO stock price is -272.55% off its 52-week high price of $3.80 and 55.88% above the 52-week low of $0.45.
The consensus among analysts is that Channel Therapeutics Corporation (CHRO) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Channel Therapeutics Corporation (AMEX:CHRO) trade information
Sporting -4.67% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CHRO stock price touched $1.02 or saw a rise of 11.3%. Year-to-date, Channel Therapeutics Corporation shares have moved 59.13%, while the 5-day performance has seen it change -6.42%. Over the past 30 days, the shares of Channel Therapeutics Corporation (AMEX:CHRO) have changed -24.44%.
Channel Therapeutics Corporation (CHRO) estimates and forecasts
The company’s shares have gained 55.13% over the past 6 months.
CHRO Dividends
Channel Therapeutics Corporation is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 0.13% shares in the company for having 8.22 shares of worth $8386.0 while later fund manager owns 1.85 shares of worth $1884.0 as of Mar 31, 2025 , which makes it owner of about 0.03% of company’s outstanding stock.
